Corcept Completes Enrollment in Phase II ALS Study
| CORT Stock | USD 58.60 0.02 0.03% |
Slightly above 51% of Corcept Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Corcept Therapeutics Incorporated stock suggests that many investors are impartial at this time. Corcept Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Corcept Therapeutics' earnings reports, geopolitical events, and overall market trends.
Corcept |
The phase II DAZALS study is evaluating Corcepts dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Read at zacks.com
 |
Corcept Therapeutics Fundamental Analysis
We analyze Corcept Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Corcept Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Corcept Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Corcept Therapeutics stock to make a market-neutral strategy. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics with similar companies.
Peers
Corcept Therapeutics Related Equities
| DYN | Dyne Therapeutics | 6.50 | ||||
| GLUE | Monte Rosa | 5.93 | ||||
| SNSE | Sensei Biotherapeutics | 5.66 | ||||
| ERAS | Erasca | 5.04 | ||||
| MLYS | Mineralys Therapeutics, | 4.71 | ||||
| NUVB | Nuvation Bio | 3.21 | ||||
| MGTX | MeiraGTx Holdings | 2.50 | ||||
| KROS | Keros Therapeutics | 2.02 | ||||
| RARE | Ultragenyx | 1.63 | ||||
| HALO | Halozyme Therapeutics | 1.42 | ||||
| IDYA | Ideaya Biosciences | 0.78 | ||||
| CYTK | Cytokinetics | 0.38 | ||||
| EWTX | Edgewise Therapeutics | 0.37 | ||||
| INSM | Insmed | 0.26 | ||||
| ANAB | AnaptysBio | 0.51 | ||||
| AGIO | Agios Pharm | 0.74 | ||||
| NXTC | NextCure | 2.50 |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.